Two radically resected colorectal carcinoma cases with unresectable liver metastasis after adjuvant chemotherapy with bevacizumab

Masahiko Sugiyama, Yoshihiro Kakeji, Nobuhide Kubo, Tomonori Nakanoko, Yoshihiko Fujinaka, Kouji Ando, Takanobu Masuda, Kenji Yagi, Keishi Yoshinaga, Hiroshi Saeki, Kazuya Endo, Yasunori Emi, Masaru Morita, Yoshihiko Maehara

Research output: Contribution to journalArticle

Abstract

Nowadays, the advancements of systemic chemotherapy for colorectal carcinoma improve a clinical response rate, and expand the possibility of resection which couldn't operable at the initial visit. In addition, the prognoses of the patients, who had a radical operation for metastasis, are clearly longer than the non-operable patients. Bevacizumab, anti-human VEGF monoclonal antibody, is significantly effective when used in combination with one of the systemic multi-agent chemotherapy such as FOLFOX regimen or FOLFIRI regimen. We report here two cases with colon carcinoma, which had initially unresectable liver metastases, were respond to the treatment of systemic multi-agent chemotherapy with bevacizumab. Then, both cases were able to undergo radical resections of primary tumor and liver metastases safely.

Original languageEnglish
Pages (from-to)2169-2171
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number12
Publication statusPublished - Nov 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Two radically resected colorectal carcinoma cases with unresectable liver metastasis after adjuvant chemotherapy with bevacizumab'. Together they form a unique fingerprint.

  • Cite this

    Sugiyama, M., Kakeji, Y., Kubo, N., Nakanoko, T., Fujinaka, Y., Ando, K., Masuda, T., Yagi, K., Yoshinaga, K., Saeki, H., Endo, K., Emi, Y., Morita, M., & Maehara, Y. (2009). Two radically resected colorectal carcinoma cases with unresectable liver metastasis after adjuvant chemotherapy with bevacizumab. Japanese Journal of Cancer and Chemotherapy, 36(12), 2169-2171.